Effects of PSA Removal from NCAM on the Critical Period Plasticity Triggered by the Antidepressant Fluoxetine in the Visual Cortex
View/ Open
Date
2016Author
Guirado, Ramón
La Terra, Danilo
Bourguignon, Mathieu
Carceller, Hector
Umemori, Juzoh
Sipilä, Pia
Nacher, Juan
Castrén, Eero
Metadata
Show full item record
Guirado R, La Terra D, Bourguignon M, Carceller H, Umemori J, Sipilä P, Nacher J and Castrén E (2016) Effects of PSA Removal from NCAM on the Critical Period Plasticity Triggered by the Antidepressant Fluoxetine in the Visual Cortex. Front. Cell. Neurosci. 10:22. doi: 10.3389/fncel.2016.00022
Abstract
Neuronal plasticity peaks during critical periods of postnatal development and is reduced
towards adulthood. Recent data suggests that windows of juvenile-like plasticity can
be triggered in the adult brain by antidepressant drugs such as Fluoxetine. Although
the exact mechanisms of how Fluoxetine promotes such plasticity remains unknown,
several studies indicate that inhibitory circuits play an important role. The polysialylated
form of the neural cell adhesion molecules (PSA-NCAM) has been suggested to mediate
the effects of Fluoxetine and it is expressed in the adult brain by mature interneurons.
Moreover, the enzymatic removal of PSA by neuroaminidase-N not only affects the
structure of interneurons but also has been shown to play a role in the onset of critical
periods during development. We have here used ocular dominance plasticity in the
mouse visual cortex as a model to investigate whether removal of PSA might influence
the Fluoxetine-induced plasticity. We demonstrate that PSA removal in the adult visual
cortex alters neither the baseline ocular dominance, nor the fluoxetine-induced shift
in the ocular dominance. We also show that both chronic Fluoxetine treatment and
PSA removal independently increase the basal FosB expression in parvalbumin (PV)
interneurons in the primary visual cortex. Therefore, our data suggest that although
PSA-NCAM regulates inhibitory circuitry, it is not required for the reactivation of juvenilelike
plasticity triggered by Fluoxetine.